Rocksauce Fiery Hot Pain Relief

Methyl Salicylate, Menthol, Capsaicin


Implus Footcare, Llc
Human Otc Drug
NDC 81683-112
Rocksauce Fiery Hot Pain Relief also known as Methyl Salicylate, Menthol, Capsaicin is a human otc drug labeled by 'Implus Footcare, Llc'. National Drug Code (NDC) number for Rocksauce Fiery Hot Pain Relief is 81683-112. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Rocksauce Fiery Hot Pain Relief drug includes Capsaicin - .00724 g/355mL Menthol - 36.2 g/355mL Methyl Salicylate - 72.4 g/355mL . The currest status of Rocksauce Fiery Hot Pain Relief drug is Active.

Drug Information:

Drug NDC: 81683-112
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Rocksauce Fiery Hot Pain Relief
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Methyl Salicylate, Menthol, Capsaicin
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Implus Footcare, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CAPSAICIN - .00724 g/355mL
MENTHOL - 36.2 g/355mL
METHYL SALICYLATE - 72.4 g/355mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 18 Mar, 2021
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 25 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Implus Footcare, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:S07O44R1ZM
L7T10EIP3A
LAV5U5022Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
81683-112-01355 mL in 1 BOTTLE (81683-112-01)18 Mar, 2021N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose topical analgesic

Product Elements:

Rocksauce fiery hot pain relief methyl salicylate, menthol, capsaicin ammonium acryloyldimethyltaurate/vp copolymer arnica montana flower aloe vera leaf cetostearyl alcohol maltodextrin ethylhexylglycerin water menthol menthol phenoxyethanol propylene glycol potassium cetyl phosphate .alpha.-tocopherol acetate capsaicin capsaicin carbomer interpolymer type a (allyl sucrose crosslinked) methyl salicylate salicylic acid aminomethylpropanol

Indications and Usage:

Uses: provides soothing heat to sore muscles and joints.

Warnings:

Warnings: for external use only. avoid contact with eyes, mucous membrane or broken skin.

Do Not Use:

Warnings: for external use only. avoid contact with eyes, mucous membrane or broken skin.

When Using:

When using this product, do not: heat, microwave, add to hot water or any container where heating water may cause splattering and result in burns, use in eyes or directly on mucus membrane, take by mouth or place in nostrils, apply to wounds or damaged skin.

Dosage and Administration:

Directions: apply liberally to area of pain and massage until lotion is absorbed into the skin. repeat 3-4 times daily. store at 68° to 77 ℉(20° to 25℃).

Package Label Principal Display Panel:

Image of bottle label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.